Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 6
1952 7
1953 10
1954 14
1955 16
1956 7
1957 5
1958 8
1959 8
1960 1
1964 4
1965 22
1966 36
1967 44
1968 72
1969 94
1970 103
1971 143
1972 185
1973 202
1974 199
1975 248
1976 185
1977 157
1978 184
1979 175
1980 187
1981 195
1982 232
1983 308
1984 329
1985 330
1986 339
1987 318
1988 309
1989 380
1990 434
1991 535
1992 588
1993 682
1994 792
1995 895
1996 909
1997 1021
1998 1058
1999 1211
2000 1270
2001 1411
2002 1550
2003 1646
2004 1669
2005 1992
2006 1979
2007 2097
2008 2160
2009 2240
2010 2441
2011 2693
2012 2944
2013 3091
2014 3434
2015 3379
2016 3308
2017 3395
2018 3366
2019 3240
2020 3124
2021 2940
2022 2468
2023 2135
2024 905

Text availability

Article attribute

Article type

Publication date

Search Results

67,397 results

Results by year

Filters applied: . Clear all
Page 1
Pathobiology of liver fibrosis: a translational success story.
Lee YA, Wallace MC, Friedman SL. Lee YA, et al. Gut. 2015 May;64(5):830-41. doi: 10.1136/gutjnl-2014-306842. Epub 2015 Feb 13. Gut. 2015. PMID: 25681399 Free PMC article. Review.
Reversibility of hepatic fibrosis and cirrhosis following antiviral therapy for hepatitis B or C has advanced the prospect of developing antifibrotic therapies for patients with chronic liver diseases, especially non-alcoholic steatohepatitis. ...Progress is urgently neede …
Reversibility of hepatic fibrosis and cirrhosis following antiviral therapy for hepatitis B or C has advanced the prospect of develop …
Corticosteroid therapy of alcoholic hepatitis.
Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Maddrey WC, et al. Gastroenterology. 1978 Aug;75(2):193-9. Gastroenterology. 1978. PMID: 352788 Clinical Trial.
Fifty-five patients with alcoholic hepatitis were studied in a 28- to 32-day randomized double blind treatment trial comparing prednisolone (40 mg per day) with placebo therapy. ...These studies suggest that corticosteroid therapy does decrease early mortalit …
Fifty-five patients with alcoholic hepatitis were studied in a 28- to 32-day randomized double blind treatment trial co …
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.
Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, Mitchell MC, Morgan TR, Nagy L, Radaeva S, Sanyal A, Shah V, Szabo G; NIAAA Alcoholic Hepatitis Consortia. Crabb DW, et al. Gastroenterology. 2016 Apr;150(4):785-90. doi: 10.1053/j.gastro.2016.02.042. Epub 2016 Feb 24. Gastroenterology. 2016. PMID: 26921783 Free PMC article. No abstract available.
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials.
Gane E, Lim YS, Kim JB, Jadhav V, Shen L, Bakardjiev AI, Huang SA, Cathcart AL, Lempp FA, Janas MM, Cloutier DJ, Kaittanis C, Sepp-Lorenzino L, Hinkle G, Taubel J, Haslett P, Milstein S, Anglero-Rodriguez YI, Hebner CM, Pang PS, Yuen MF. Gane E, et al. J Hepatol. 2023 Oct;79(4):924-932. doi: 10.1016/j.jhep.2023.05.023. Epub 2023 Jun 7. J Hepatol. 2023. PMID: 37290591 Free article.
The HBsAg reduction was maintained at 0.87 log IU/ml at Week 48. No participants had serum HBsAg loss or hepatitis B surface antibody seroconversion. CONCLUSIONS: VIR-2218 demonstrated an encouraging hepatic safety profile in preclinical and clinical studies as well …
The HBsAg reduction was maintained at 0.87 log IU/ml at Week 48. No participants had serum HBsAg loss or hepatitis B surface antibody …
Hepatitis E virus.
Khuroo MS, Khuroo MS. Khuroo MS, et al. Curr Opin Infect Dis. 2008 Oct;21(5):539-43. doi: 10.1097/QCO.0b013e32830ee08a. Curr Opin Infect Dis. 2008. PMID: 18725805 Review.
Recent reports have documented hepatitis E virus causing chronic hepatitis and cirrhosis in patients after solid organ transplantation. ...A recombinant hepatitis E vaccine has been evaluated in a phase 2, randomized, placebo-controlled trial in …
Recent reports have documented hepatitis E virus causing chronic hepatitis and cirrhosis in patients after solid organ transpl …
Controversies in clinical trials for alcoholic hepatitis.
Lieber SR, Rice JP, Lucey MR, Bataller R. Lieber SR, et al. J Hepatol. 2018 Mar;68(3):586-592. doi: 10.1016/j.jhep.2017.09.013. Epub 2017 Sep 28. J Hepatol. 2018. PMID: 28966126 Free PMC article. Review.
Alcoholic hepatitis (AH) is the most severe form of alcoholic liver disease, contributing to significant morbidity and mortality. ...Ultimately, we suggest that the field will advance with the development of a plausible animal model of true AH, a consensus on a composite …
Alcoholic hepatitis (AH) is the most severe form of alcoholic liver disease, contributing to significant morbidity and mortality. ... …
CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) Update.
Lee GH, Lim SG. Lee GH, et al. Expert Rev Vaccines. 2021 May;20(5):487-495. doi: 10.1080/14760584.2021.1908133. Epub 2021 Apr 9. Expert Rev Vaccines. 2021. PMID: 33783302 Review.
Introduction: HEPLISAV-B is a hepatitis B vaccine composed of rHBsAg mixed with a synthetic oligonucleotide containing CpG motifs that stimulate innate immunity through TLR9. ...The shorter, two-dose regimen, earlier seroprotection, higher adherence, and a higher seroprote …
Introduction: HEPLISAV-B is a hepatitis B vaccine composed of rHBsAg mixed with a synthetic oligonucleotide containing CpG motifs tha …
Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis.
Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Fialla AD, et al. Liver Int. 2015 Sep;35(9):2072-8. doi: 10.1111/liv.12798. Epub 2015 Feb 15. Liver Int. 2015. PMID: 25645300 Review.
Sequential analyses were performed to evaluate the risk of spurious findings because of random and systematic errors. Subgroup and sensitivity analyses were performed to evaluate the risk of bias and sources of between trial heterogeneity. ...Fixed-effect analysis s …
Sequential analyses were performed to evaluate the risk of spurious findings because of random and systematic errors. Subgroup and se …
Clinical Trial Design for Alcoholic Hepatitis.
Szabo G. Szabo G. Semin Liver Dis. 2017 Nov;37(4):332-342. doi: 10.1055/s-0037-1608788. Epub 2017 Dec 22. Semin Liver Dis. 2017. PMID: 29272895 Review.
Alcoholic hepatitis (AH) is an acute and clinically distinct manifestation of alcoholic liver disease. ...There are remaining challenges in designing clinical trials in AH that include definition of the severity of disease, common data elements in clinical …
Alcoholic hepatitis (AH) is an acute and clinically distinct manifestation of alcoholic liver disease. ...There are remaining challen …
Blinding in Clinical Trials for Chronic Liver Diseases.
Ortiz V, Ellenberg SS, Weinberg EM. Ortiz V, et al. Semin Liver Dis. 2021 May;41(2):163-171. doi: 10.1055/s-0041-1723753. Epub 2021 May 6. Semin Liver Dis. 2021. PMID: 33957695 Review.
Within the field of randomized clinical trials (RCTs), the randomized double-blind placebo-controlled clinical trial is considered the most efficient means of simultaneously assessing the efficacy and safety of a medical therapy in a single t …
Within the field of randomized clinical trials (RCTs), the randomized double-blind placebo-controlled clinical …
67,397 results
You have reached the last available page of results. Please see the User Guide for more information.